Recipient: Charité – University of Berlin
Funding: Go-Bio initial (01/10/2022 to 30/09/2023, EUR 119,895.65)

Project description:

Cancer remains the second leading cause of death in Europe and worldwide. In particular, extensive tumour involvement is difficult to treat. A well-tolerated local adjunctive therapy that uses so-called modulated electromagnetic radio-frequency fields (in short: radio waves) has the potential to significantly improve existing standard therapies. For this purpose, radio waves are used, which use known differences between cancer cells and healthy tissue for selective local treatment. In the project suitable radio waves (carrier and modulation frequencies) are first identified by means of physical measurements, which lead to the highest possible energy absorption and thus to non-temperature-induced anti-tumour effects in the tumour cells. The specific treatment with the radio waves determined in this way is to be carried out with specially modified transmitter and amplifier electronics. The aim of the project is to develop a new treatment device that enhances the effect of available cancer therapies in a highly effective and gentle manner in the sense of personalised therapy and can thus improve the overall prognosis of cancer. Among other things the exploratory phase will be used to review the legal and regulatory viability of the idea. Patent landscape, market and competition analyses will additionally be used to clarify whether and how the exploitation of the results of radio-frequency therapy can be driven forward.